Purpose: To develop citrate crosslinked chitosan films using chitosan of different molecular weights (MW) 
INTRODUCTION
A major feature of medicines development today is the design of suitable vehicles for drug delivery. Delivery vehicles for therapeutic compounds must be biocompatible and nontoxic [1] . Many of these systems are pH/thermo-sensitive or osmotically driven [2] . Thin polymer films have also been employed to control drug release for various routes of administration, such as transdermal, colonic, localized, and ophthalmic. Mucoadhesive polymeric film formulations can circumvent limitations caused by conventional vaginal formulations such as tablets and creams [3] . For example, the release of paclitaxel from PVP-g-PLGA film was found to be continuous and not preceded by initial drug burst [4] .
Time-or pH-dependent polymers are often used to target delivery of therapeutic substances to sites of action [5] . Several studies have associated drug release kinetics with the type of drug and device geometry. For instance, Klose et al studied these factors in PLGA-based drug delivery systems [6] while results from other studies indicate that polymer films are promising carriers for ophthalmic, localized and transdermal drug delivery systems [7] . Various polymethacrylate films have been evaluated for insulin colonic drug delivery [8] .
Chitosan [α (1-4) 2-amino-2-deoxy-beta-DGlucan] is the deacetylated derivative of chitin. It has recently attracted much interest in the biomedical industry because of its biodegradability, biocompatibility, antimicrobial activity, and accelerated wound healing properties [9] . Due to its unique polymeric cationic character as well as gel and film forming properties, chitosan has been extensively examined for various pharmaceutical applications. Several drug delivery formulations based on chitosan, such as film, beads, microspheres, etc, have been prepared using chemical cross-linking methods. For example, Emmanuel et al demonstrated the in vitro and in vivo zeroorder drug release properties and biocompatibility of a chitosan-based implantable film and its potential usefulness in the sustained and local delivery of antineoplastic agents such as paclitaxel [10] .
When chitosan is dissolved in dilute acetic acid solutions, the amino groups become protonated and associated with acetate counter-ions, making the charged polymer soluble [11] . Chitosan films have been usually prepared by chemical crosslinking via electrostatic interaction between multivalent phosphates and chitosan in the formulation [12] . Chitosan crosslinked films swell under acidic conditions due to the ionization of amino groups but remains in a shrunken state under neutral conditions. Chitosan itself has intragastric-floating characteristics and can cause prolonged retention of the dosage form in the stomach [13] .
Controlled release of ciprofloxacin hydrochloride from chitosan/polyethylene glycol blend films produced by the castingsolvent evaporation method has been evaluated [14] . It has also been shown that due to electrostatic interaction between sodium citrate and chitosan, citrate/chitosan film may be useful in drug delivery such as site-specific controlled release in stomach and also as epidermal sheets for humans, rats, and rabbits [15] . Polymer molecular weight has a major effect on chitosan properties [16] , and it has also been shown that the thermo-sensitive characteristics, appearance and structure of the hydrogel as well as drug release from it are affected by chitosan MW and degree of deacetylation [17] . In this paper, we sought to prepare citrate-crosslinked chitosan films using three different molecular weights (MWs) of chitosan and investigated whether or not chitosan MW affects some properties of the indomethacincontaining films.
EXPERIMENTAL Materials
Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid), produced by Medichem, Spain, was used as a model hydrophobic drug. Low, medium and high molecular weight grades of chitosan (85 % deacetylation) were purchased from Fluka AG, Switzerland while sodium citrate (analytical grade) and other reagents were purchased locally and used as received.
Turbidimetric titration
The interaction between sodium citrate and chitosan was investigated by turbidimetric titration [18] . Briefly, a solution of 0.2 g/L sodium citrate and 0.2 g/L chitosan at pH 1.0 was prepared. The titrant (0.2M NaOH) was delivered with a microburette into 50 ml of the citrate/chitosan solution with constant stirring at 25 ± 0.5 °C and with the pH monitored by a digital pH meter (Metrohm 780, Switzerland). Changes in turbidity were monitored at 420 nm with an UV-Vis spectrophotometer (Genesys TM2, USA and reported as 100 % transmittance.
Preparation of crosslinked chitosan films
Chitosan solution (4 %w/v), was prepared by dissolving chitosan in 4 %w/v acetic acid and then indomethacin (1 %w/v) was dispersed in the solution. This was done for each MW grade of chitosan. The mixture (100 ml) was left to stand until trapped air bubbles disappeared and then was poured on a glass plate. The poured solution was allowed to dry in a hot air oven (Pars Azma 1597) at 37 °C to constant weight. The resulting dry films were cut into 4 cm diameter disks and crosslinked soaking in 100 ml aqueous solution of sodium citrate 4 °C.
Other crosslinking conditions were: 0.5 -10 %w/v sodium citrate; solution pH of 5 -7; and crosslinking time of 0.5 -4.0 h. The crosslinked films were then rinsed in 20 ml of distilled water, transferred to a glass plate and oven-dried at 37 °C to a constant weight. Drug loss during the crosslinking process was determined spectrophotometrically at 318 nm.
Measurement of film thickness
The thickness of the dried films was measured with a micrometer (model 2050-08, Mitutoyo, Japan). Five measurements were taken at randomly selected points on each specimen and the mean thickness taken.
Morphological studies
The surface morphology of the crosslinked films was assessed by scanning electron microscopy (model 2360, Leo Oxford, England) after the films were first coated with gold.
Evaluation of swelling ratio
Blank citrate/chitosan films were suspended in glass bottles containing 250 ml of medium (either phosphate buffer, pH 6.2, or acetate buffer, pH 3.5) and placed in a shaker waterbath (at 37 °C, 50 rpm). At 30 min intervals, the films were taken out, the excess water blotted out carefully with filter paper from the film surface and then weighed immediately. The swelling ratio (W t /W 0 ) was determined (where W t was the film weight at time t and W 0 was the initial film weight).
Release studies
Indomethacin release from the films was evaluated by USP dissolution method V (paddle over disk method) in 750 ml phosphate buffer (pH 6.2) or acetate buffer (pH 3.5) at 37 °C and at a stirring rate of 50 rpm, using Erweka dissolution tester (model DT 80). Samples (5 ml) were withdrawn from the medium at various time intervals and the medium replenished immediately with the same volume of fresh dissolution medium. The amount of dissolved indomethacin in the sample taken was measured (after filtration) spectrophotometrically at 318 nm. where Cn = true concentration of sample, Cnmass = apparent concentration of sample, V = volume of sample, and Vt = total volume of dissolution fluid.
Differential scanning calorimetry (DSC)
Differential scanning calorimetric studies were conducted in a Perkin Elmer DSC facility,using a sample size of approx. 5 mg in a loosely covered aluminum pan and heated in nitrogen atmosphere from 50 to 250 °C at a rate of 10°C/min. An empty loosely covered aluminum pan was used as the reference.
Statistical analysis
Experimental results were expressed as mean ± standard deviation (SD). Student's ttest and one-way analysis of variance (ANOVA) were applied to check significant differences in drug release, and swelling studies for different film formulations. Differences were considered to be statistically significant at p < 0.05. Table 1 shows the mean thickness and drug content of the films prepared at varying combinations of crosslinking concentration and time. The results show that there was no significant difference (p > 0.05) between the films in terms of film thickness or drug content.
RESULTS

Film thickness and drug content
Citrate -chitosan interaction
The turbidimetric titration curve of sodium citrate/chitosan (not shown) indicated that in acidic conditions (pH 1 -4), the solution was clear; thereafter, it became turbid as the pH further rose but reverted to a clear solution (i.e., no interaction) at pH ≥ 7. 
Film appearance
SEM photomicrographs (not shown) indicate that the inner surface of the films (which interfaced with the glass plate) was smooth while the outer surface was relatively rough. Crosslinking hardly had any noticeable effect on the surface morphology of the films. However, all the films were yellowish cream in colour, with the colour deepening and film texture becoming more tender with increase in crosslinking time.
Swelling ratio
The swelling data are shown in Fig 1. They indicate that at pH 6.2, film swelling for all three chitosan MW grades was significantly (p < 0.05) affected by crosslinking time. All the MW grades showed higher swelling in acid conditions (pH 3.5) than at pH 6.2. Furthermore, at pH of 3.5, swelling decreased as MW of chitosan rose. Drug release studies: Table 1 Table 1) There was no significant difference between low and medium MW grades of chitosan in terms of the drug release rate of the films (p > 0.05). However, high MW chitosan film showed a slight decrease in the rate of drug release in acid conditions.
Thermal characteristics
The DSC thermograms of pure indomethacin and some of the chitosan films are shown in 
DISCUSSION
Citrate is an anion with three carboxylic groups and chitosan is polybasic with cations. The charge densities of citrate and chitosan are mainly controlled by solution pH [13] [14] .
Under neutral and weakly acidic conditions, the degree of ionization of sodium citrate significantly decreased owing to the weak acid characteristics of citric acid. In contrast, chitosan, being a weak polybase, showed a marked decrease in the ionization of its amine groups when solution pH increased to over 6.0 (chitosan pKa = 6.3) [19] . Table 1 )
Film swelling
The pH of the medium had a major effect on chitosan film swelling due to the ionization of both the sodium citrate and chitosan. Swelling ratio was lowest at pH of 5.5 and 6.5, owing to electrostatic attraction between citrate and chitosan. Reduction in pH weakened the salt bonds and, therefore, facilitated chitosan film swelling. However, increase in pH above 6.5 would probably also have weakened the salt-bonds and produced a higher swelling ratio.
Drug release
Drug release from the films was sensitive to pH because electrostatic interaction between the citrate anion and chitosan amine groups were influenced by solution pH. Decrease in pH weakened the salt bonds and therefore, facilitated film swelling, thereby making it more porous and accelerating drug release. pH also has been reported to have a slight effect on the solubility of indomethacin [20] . A lower pH leads to improved solubility of drug and this in turn results in higher drug release rate. However, compared to the strong influence of pH on the film matrix, pH effects on drug solubility was negligible. At low pH (1.0 -3.5), sodium citrate and chitosan would be in a dissociated state and hence drug release from the films was rapid. As the results show the greater the crosslinking time, the lower was the drug release rate, This may be attributed to a higher degree of crosslinking in the matrix, leading to delay in the diffusional release of the drug. A slight decrease in the rate of drug release in acid conditions for high MW chitosan film maybe related to its higher viscosity compared with low and medium MWs.
Although the protonation constant (pKa) of chitosan slightly decreases (from 6.51 to 6.39) with decrease in its MW [19] , in acid conditions (pH 3.5), a slight decrease in pKa appeared not to have played a major role in drug release rate due to high dissociation at all chitosan MWs.
Thermal characteristics
The absence of a sharp endothermic melting peak for indomethacin in the thermograms of these films may be due to the conversion of the incorporated indomethacin from the crystalline to the more soluble amorphous state.
CONCLUSION
The variations in citrate-crosslinked chitosan film swelling and as well as in drug release rate in medium pH of 3.5 and 6.2 suggest that this type of films can be modulated to achieve site-specific delivery in the stomach.
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